线粒体DNA拷贝数作为卒中预后标志物与中介因素:观察性与孟德尔随机化分析
基于INTERSTROKE研究3498例急性首发性卒中病例,发现基线白细胞层线粒体DNA拷贝数(mtDNA-CN)每降低1个标准差与卒中严重程度、1个月残疾、不良功能结局及死亡风险升高相关,且孟德尔随机化分析提示低mtDNA-CN可能是3个月结局的因果决定因素。
要点
- 基线mtDNA-CN每降低1个标准差,1个月死亡风险升高(OR 1.35,95%CI 1.14-1.59)。
- mtDNA-CN可改善不良功能结局(NRI 0.16)和死亡(NRI 0.31)的风险重分类。
- 孟德尔随机化提示遗传决定的mtDNA-CN降低与3个月不良功能结局风险升高相关(OR 2.68)。
核心结论
- 白细胞层mtDNA-CN是卒中后预后的一种新型稳健标志物,也可能为卒中后结局的因果决定因素。
研究设计与样本
- 研究纳入来自25个国家的国际多中心病例对照研究INTERSTROKE中3498例急性首发性卒中病例,进行基线mtDNA-CN与1个月结局的关联分析。
- 采用两样本孟德尔随机化分析,mtDNA-CN遗传变异来自UK Biobank研究(N=383,476),对3个月改良Rankin量表(mRS)评分的影响来自GISCOME研究(N=6,021)。
主要发现
- 基线mtDNA-CN每降低1个标准差与卒中严重程度相关(基线mRS评分:OR 1.27,95%CI 1.19-1.36;p=4.7×10⁻¹²)。
- 独立于基线卒中严重程度,mtDNA-CN每降低1个标准差与1个月残疾增加(序贯mRS评分:OR 1.16,95%CI 1.08-1.24;p=4.4×10⁻⁵)、不良功能结局(mRS评分3-6 vs 0-2:OR 1.21,95%CI 1.08-1.34;p=6.9×10⁻⁴)及死亡(OR 1.35,95%CI 1.14-1.59;p=3.9×10⁻⁴)相关。
- 亚组分析显示在卒中类型、性别、年龄、国家收入水平和教育水平方面效应一致。
- mtDNA-CN在已知预后因素之外显著改善不良功能结局(NRI 0.16,95%CI 0.08-0.23;p=3.6×10⁻⁵)和死亡(NRI 0.31,95%CI 0.19-0.43;p=1.7×10⁻⁷)的风险重分类。
- 孟德尔随机化显示遗传决定的mtDNA-CN每降低1个标准差与3个月序贯mRS评分增加(OR 2.35,95%CI 1.13-4.90;p=0.02)及不良功能结局(OR 2.68,95%CI 1.05-6.86;p=0.04)相关。
关键数值与推荐
- 该研究提供II级证据:低白细胞层mtDNA-CN(>1个标准差)与缺血性或出血性卒中患者更差的基线严重程度和1个月结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Low buffy coat mitochondrial DNA copy number (mtDNA-CN) is associated with incident risk of stroke and poststroke mortality; however, its prognostic utility has not been extensively explored. Our goal was to investigate whether low buffy coat mtDNA-CN is a marker and causal determinant of poststroke outcomes using epidemiologic and genetic studies. METHODS: First, we performed association testing between baseline buffy coat mtDNA-CN measurements and 1-month poststroke outcomes in 3,498 cases of acute, first stroke from 25 countries from the international, multicenter case-control study Importance of Conventional and Emerging Risk Factors of Stroke in Different Regions and Ethnic Groups of the World (INTERSTROKE). Then, we performed 2-sample mendelian randomization analyses to evaluate potential causative effects of low mtDNA-CN on 3-month modified Rankin Scale (mRS) score. Genetic variants associated with mtDNA-CN levels were derived from the UK Biobank study (N = 383,476), and corresponding effects on 3-month mRS score were ascertained from the Genetics of Ischemic Stroke Functional Outcome (GISCOME; N = 6,021) study. RESULTS: A 1-SD lower mtDNA-CN at baseline was associated with stroke severity (baseline mRS score: odds ratio [OR] 1.27, 95% confidence interval [CI] 1.19-1.36; p = 4.7 × 10-12). Independently of baseline stroke severity, lower mtDNA-CN was associated with increased odds of greater 1-month disability (ordinal mRS score: OR 1.16, 95% CI 1.08-1.24; p = 4.4 × 10-5), poor functional outcome status (mRS score 3-6 vs 0-2: OR 1.21, 95% CI 1.08-1.34; p = 6.9 × 10-4), and mortality (OR 1.35, 95% CI 1.14-1.59; p = 3.9 × 10-4). Subgroup analyses demonstrated consistent effects across stroke type, sex, age, country income level, and education level. In addition, mtDNA-CN significantly improved reclassification of poor functional outcome status (net reclassification index [NRI] score 0.16, 95% CI 0.08-0.23; p = 3.6 × 10-5) and mortality (NRI score 0.31, 95% CI 0.19-0.43; p = 1.7 × 10-7) beyond known prognosticators. With the use of independent datasets, mendelian randomization revealed that a 1-SD decrease in genetically determined mtDNA-CN was associated with increased odds of greater 3-month disability quantified by ordinal mRS score (OR 2.35, 95% CI 1.13-4.90; p = 0.02) and poor functional outcome status (OR 2.68, 95% CI 1.05-6.86; p = 0.04). DISCUSSION: Buffy coat mtDNA-CN is a novel and robust marker of poststroke prognosis that may also be a causal determinant of poststroke outcomes. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that low buffy coat mtDNA-CN (>1 SD) was associated with worse baseline severity and 1-month outcomes in patients with ischemic or hemorrhagic stroke.
引用
- Chong MR, Narula S, Morton R, et al. Mitochondrial DNA Copy Number as a Marker and Mediator of Stroke Prognosis: Observational and Mendelian Randomization Analyses. Neurology. 2021. PMID: 34880091. doi:10.1212/WNL.0000000000013165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。